Twitter

Facebook

Youtube

RSS

Hindi News | Samay | UP/Uttarakhand | MP/Chhattisgarh | Bihar/Jharkhand | Rajasthan | Aalami Samay
  Rashtriya Sahara Roznama Sahara
Shashi Tharoor criticises govt nod to Bharat Biotech vaccine without phase-3 trials
Last Updated : 04 Jan 2021 02:35:46 PM IST
Congress leader Shashi Tharoor
Congress leader Shashi Tharoor

 

Congress leader Shashi Tharoor has criticised the government for giving the nod to Bharat Biotech's Covid vaccine without phase-3 trials.

Tharoor said, "This is all we are saying. Of course, we will be proud if the vaccine turns out to work effectively. But offering it before phase-3 clinical trials have proven its efficacy is a violation of every scientific protocol and unheard of in the world. Jingoism is no substitute for common sense."
 
Earlier on Sunday, Drug Controller General of India (DCGI) V.G. Somani announced that Bharat Biotech's 'Covaxin' has been approved for "restricted use in emergency situations". The approval has also been given to Serum Institute of India's 'Covishield' vaccine.
 
Tharoor added, "But the Health Minister saying 'it's more likely to work' and 'it's likely to have similar protective efficacy reported for others' is not reassuring. 'Likely' can only be 'certain' after phase-3 clinical trials."
 
The Subject Expert Committee of the Central Drugs Standards Control Organisation had recommended restricted use of Covaxin "in emergency situations in public interest as an abundant precaution, in clinical trial mode, specially in the context of infection by mutant strains".
 
Officials say that it will be used as backup in case of a spike in cases.
 
Covaxin has to be administered in two doses and can be stored at 2-8 degree Celsius. This is a major relief for India which has the second highest number of infections in the world after the US.
 
Bharat Biotech has made India's first indigenous vaccine for coronavirus. The inactivated virus vaccine has been developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

"Covaxin has generated excellent safety data with robust immune responses to multiple viral proteins that persist," Krishna Ella, Chairman and Managing Director of the pharmaceutical company said following the approval.



IANS
New Delhi
For Latest Updates Please-

Join us on

Follow us on


What binds the two most talked about nations - India and Pakistan together? What makes the

Bollywood actress Sonakshi Sinha is enjoying her marital bliss. On Monday, the actress too

LG Electronics Inc said on Wednesday that it will introduce new C with its artificial inte

 

Samay Live
Samay Live
Samay Live
Samay Live
Samay Live
Samay Live
Samay Live
Samay Live

172.31.16.186